Evaluate Vantage takes a look at the still-open deals that might come under threat from a new international clampdown.
A filing in pyruvate kinase deficiency beckons, but bigger indications could be trickier.
One of the biggest surprises of 2020 was how biopharma M&A emerged relatively unscathed from Covid-19.
Selling its cancer drugs to Servier leaves Agios more reliant on mitapivat.
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Evaluate Vantage's coverage of the virtual Ash 2020 congress.